Kidney stones and metabolic bone diseases not linked to parathyroid disfunction: a proposal for an integrated management

Nephrolithiasis (KS) and metabolic bone diseases (MBDs) not linked to parathormone (osteoporosis, Paget’s disease of bone and renal phosphate leak) are related as demonstrated by epidemiological and experimental data. Moreover, patients affected by monogenic kidney stone disorders (idiopathic hypercalciuria, primary hyperoxaluria, hypocitraturia, cystinuria and defects in purine metabolism) showed a bone phenotype. A significant economic and social burden is associated with KS and MBDs, due to high mortality and morbidity rate. Concerning this point of view, an integrated screening could be a cost-saving strategy. We suggest a new clinical management for patients affected by KS and MBDs. The assessment of bone mineral density by Dual X-ray absorptiometry and bone turnover markers should be proposed in KS patients. On the contrary, the evaluation of KS-related metabolic risk factor and an abdomen ultrasound exam should be offered to MBD patients. Moreover, in patients with early and/or recurrent KS, an extended gene-panel should be suggested.

Karsenty G. The complexities of skeletal biology. Nature 2003; 423:316-318. DOI: https://doi.org/10.1038/nature01654

Feng X. Chemical and biochemical basis of cell-bone matrix interaction in health and disease. Curr Chem Biol 2009; 3:189-196. DOI: https://doi.org/10.2174/2212796810903020189

Arias CF, Herrero MA, Echeverri LF, et al. Bone remodeling: a tissue-level process emerging from cell-level molecular algorithms. PLoS One 2018; 13:e0204171. DOI: https://doi.org/10.1371/journal.pone.0204171

Šromová V, Sobola D, Kaspar P. A brief review of bone cell function and importance. Cells 2023;12:2576. DOI: https://doi.org/10.3390/cells12212576

Florencio-Silva R, Sasso GR, Sasso-Cerri E, et al. biology of bone tissue: structure, function, and factors that influence bone cells. Biomed Res Int 2015; 2015:421746. DOI: https://doi.org/10.1155/2015/421746

Guntur AR, Rosen CJ. Bone as an endocrine organ. Endocr Pract 2012;18:758-62. DOI: https://doi.org/10.4158/EP12141.RA

Du Y, Zhang L, Wang Z, et al. Endocrine regulation of extra-skeletal organs by bone-derived secreted protein and the effect of mechanical stimulation. Front Cell Dev Biol 2021; 9:778015. DOI: https://doi.org/10.3389/fcell.2021.778015

Karsenty G. Osteocalcin: A multifaceted bone-derived hormone. Annu Rev Nutr. 2023;43:55-71. DOI: https://doi.org/10.1146/annurev-nutr-061121-091348

Rauner M, Sipos W, Pietschmann P. Osteoimmunology. Int Arch Allergy Immunol 2007;143:31-48. DOI: https://doi.org/10.1159/000098223

Cornish J, Gillespie MT, Callon KE, et al. Interleukin-18 is a novel mitogen of osteogenic and chondrogenic cells. Endocrinology 2003;144:1194-201. DOI: https://doi.org/10.1210/en.2002-220936

Mirosavljevic D, Quinn JM, Elliott J, et al. T-cells mediate an inhibitory effect of interleukin-4 on osteoclastogenesis. J Bone Miner Res 2003;18:984-93. DOI: https://doi.org/10.1359/jbmr.2003.18.6.984

Takayanagi H, Ogasawara K, Hida S, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000; 408:600-5. DOI: https://doi.org/10.1038/35046102

Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402:304-9. DOI: https://doi.org/10.1038/46303

Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 2010 1; 6:4. DOI: https://doi.org/10.1038/nrrheum.2009.280

Su N, Yang J, Xie Y, et al. Bone function, dysfunction and its role in diseases including critical illness. Int J Biol Sci 2019; 15:776-87. DOI: https://doi.org/10.7150/ijbs.27063

Blake GM, Fogelman I. The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgrad Med J 2007; 83:509-17. DOI: https://doi.org/10.1136/pgmj.2007.057505

Rossini M, Adami S, Bertoldo F, et al. Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo 2016; 68:1-39. DOI: https://doi.org/10.4081/reumatismo.2016.870

Rajan R, Cherian KE, Kapoor N, Paul TV. Trabecular bone score-an emerging tool in the management of osteoporosis. Indian J Endocrinol Metab 2020; 24:237-43. DOI: https://doi.org/10.4103/ijem.IJEM_147_20

Hans D, Métrailler A, Gonzalez Rodriguez E, et al. Quantitative ultrasound (QUS) in the management of osteoporosis and assessment of fracture risk: an update. Adv Exp Med Biol 2022;1364:7-34. DOI: https://doi.org/10.1007/978-3-030-91979-5_2

Brett AD, Brown JK. Quantitative computed tomography and opportunistic bone density screening by dual use of computed tomography scans. J Orthop Translat 2015;3:178-84. DOI: https://doi.org/10.1016/j.jot.2015.08.006

Diez-Perez A, Brandi ML, Al-Daghri N, et al. Radiofrequency echographic multi-spectrometry for the in-vivo assessment of bone strength: state of the art-outcomes of an expert consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res 2019;31:1375-89. DOI: https://doi.org/10.1007/s40520-019-01294-4

Di Paola M, Gatti D, Viapiana O, et al. Radiofrequency echographic multispectrometry compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck. Osteoporos Int 2019; 30:391-402. DOI: https://doi.org/10.1007/s00198-018-4686-3

Koivula MK, Risteli L, Risteli J. Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum. Clin Biochem 2012;45:920-927. DOI: https://doi.org/10.1016/j.clinbiochem.2012.03.023

Parfitt AM, Simon LS, Villanueva AR, Krane SM. Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with Iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 1987;2:427-36. DOI: https://doi.org/10.1002/jbmr.5650020510

Power MJ, Fottrell PF. Osteocalcin: diagnostic methods and clinical applications. Crit Rev Clin Lab Sci 1991;28:287-335. DOI: https://doi.org/10.3109/10408369109106867

Sprague SM, Bellorin-Font E, Jorgetti V, et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis 2016; 67:559-66. DOI: https://doi.org/10.1053/j.ajkd.2015.06.023

Brown JP, Don-Wauchope A, Douville P, et al. Current use of bone turnover markers in the management of osteoporosis. Clin Biochem 2022;109-110:1-10. DOI: https://doi.org/10.1016/j.clinbiochem.2022.09.002

Shetty S, Kapoor N, Bondu JD, et al. Bone turnover markers: emerging tool in the management of osteoporosis. Indian J Endocrinol Metab 2016; 20:846-52. DOI: https://doi.org/10.4103/2230-8210.192914

Gambaro G, Croppi E, Coe F, et al. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol 2016; 29:715-34. DOI: https://doi.org/10.1007/s40620-016-0329-y

Ziemba JB, Matlaga BR. Epidemiology and economics of nephrolithiasis. Investig Clin Urol 2017;58:299-306. DOI: https://doi.org/10.4111/icu.2017.58.5.299

Türk C, Petrík A, Sarica K, et al. EAU guidelines on diagnosis and conservative management of urolithiasis. Eur Urol 2016; 69:468-74. DOI: https://doi.org/10.1016/j.eururo.2015.07.040

Ghani KR, Rojanasarot S, Cutone B, et al. Economic burden of complicated ureteral stent removal in patients with kidney stone disease in the USA. J Comp Eff Res 2022; 11:1253-61. DOI: https://doi.org/10.2217/cer-2022-0153

Hyams ES, Matlaga BR. Economic impact of urinary stones. Transl Androl Urol. 2014;3:4200.

Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest 2005; 115:2598-608. DOI: https://doi.org/10.1172/JCI26662

Feng X, McDonald JM. Disorders of bone remodeling. Annu Rev Pathol 2011; 6:121-45. DOI: https://doi.org/10.1146/annurev-pathol-011110-130203

GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020 14; 396:1562.

Marcellusi A, Rotundo MA, Nardone C, et al. Osteoporosis: economic burden of disease in Italy. Clin Drug Investig 2020; 40:449-58.

Cundy T, et al. Metabolic bone disease in clinical biochemistry: metabolic and clinical aspects, 3rd Ed, 2014. p 604. DOI: https://doi.org/10.1016/B978-0-7020-5140-1.00031-6

Golden SH, Robinson KA, Saldanha I, et al. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009; 94:1853-78. DOI: https://doi.org/10.1210/jc.2008-2291

Appelman-Dijkstra NM, Oei HLDW, Vlug AG, Winter EM. The effect of osteoporosis treatment on bone mass. Best Pract Res Clin Endocrinol Metab 2022; 36:101623. DOI: https://doi.org/10.1016/j.beem.2022.101623

Denburg MR, Leonard MB, Haynes K, et al. Risk of fracture in urolithiasis: a population-based cohort study using the health improvement network. Clin J Am Soc Nephrol 2014; 9:2133-40. DOI: https://doi.org/10.2215/CJN.04340514

Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 2014; 25:2359-81. DOI: https://doi.org/10.1007/s00198-014-2794-2

Muñoz-Garach A, García-Fontana B, Muñoz-Torres M. Nutrients and dietary patterns related to osteoporosis. Nutrients 2020; 12:1986. DOI: https://doi.org/10.3390/nu12071986

Sorensen MD, Chi T, Shara NM, et al. Activity, energy intake, obesity, and the risk of incident kidney stones in postmenopausal women: a report from the Women's Health Initiative. J Am Soc Nephrol 2014; 25:362-9. DOI: https://doi.org/10.1681/ASN.2013050548

Booth FW, Roberts CK, Thyfault JP, et al. Role of inactivity in chronic diseases: evolutionary insight and pathophysiological mechanisms. Physiol Rev 2017; 97:1351-402. DOI: https://doi.org/10.1152/physrev.00019.2016

Amrein K, Scherkl M, Hoffmann M, et al. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr 2020;74:1498-513. DOI: https://doi.org/10.1038/s41430-020-0558-y

Howles SA, Thakker RV. Genetics of kidney stone disease. Nat Rev Urol 2020; 17:407-421. DOI: https://doi.org/10.1038/s41585-020-0332-x

Pak CY, Sakhaee K, Moe OW, et al. Defining hypercalciuria in nephrolithiasis. Kidney Int 2011; 80:777-82. DOI: https://doi.org/10.1038/ki.2011.227

Giannini S, Nobile M, Dalle Carbonare L, et al. Hypercalciuria is a common and important finding in postmenopausal women with osteoporosis. Eur J Endocrinol 2003;149:209-13. DOI: https://doi.org/10.1530/eje.0.1490209

Eller-Vainicher C, Cairoli E, Zhukouskaya VV, et al. Prevalence of subclinical contributors to low bone mineral density and/or fragility fracture. Eur J Endocrinol 2013;169:225-37. DOI: https://doi.org/10.1530/EJE-13-0102

Rebsamen MC, Sun J, Norman AW, Liao JK. 1alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res 2002;91:17-24. DOI: https://doi.org/10.1161/01.RES.0000025269.60668.0F

Trinchieri A. Bone mineral content in calcium renal stone formers. Urol Res 2005; 33:247-53. DOI: https://doi.org/10.1007/s00240-005-0498-y

Thorleifsson G, Holm H, Edvardsson V, et al. Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet 2009; 41:926-30. DOI: https://doi.org/10.1038/ng.404

Kleeman CR, Bohannan J, Bernstein D, et al. Effect of variations in sodium intake on calcium excretion in normal humans. Pro Soc Exp Biol Med 1964; 115:29-32. DOI: https://doi.org/10.3181/00379727-115-28821

Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354:669-83. DOI: https://doi.org/10.1056/NEJMx060015

Heaney RP. Calcium supplementation and incident kidney stone risk: a systematic review. J Am Coll Nutr 2008; 27:519-27. DOI: https://doi.org/10.1080/07315724.2008.10719734

Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002; 346:77-84. DOI: https://doi.org/10.1056/NEJMoa010369

Nordin BE, Need AG, Steurer T, et al. Nutrition, osteoporosis, and aging. Ann NY Acad Sci. 1998; 854:336-51. DOI: https://doi.org/10.1111/j.1749-6632.1998.tb09914.x

Nouvenne A, Meschi T, Guerra A, et al. Dietary treatment of nephrolithiasis. Clin Cases Miner Bone Metab 2008; 5:135-41.

Thom JA, Morris JE, Bishop A, Blacklock NJ. The influence of refined carbohydrate on urinary calcium excretion. Br J Urol 1978; 50:459-464. DOI: https://doi.org/10.1111/j.1464-410X.1978.tb06191.x

DiNicolantonio JJ, Mehta V, Zaman SB, O'Keefe JH. Not salt but sugar as aetiological in osteoporosis: a review. Mo Med 2018;115:247-52.

Rendina D, De Filippo G, Zampa G, et al. Characteristic clinical and biochemical profile of recurrent calcium-oxalate nephrolithiasis in patients with metabolic syndrome. Nephrol Dial Transplant 2011; 26:2256-63. DOI: https://doi.org/10.1093/ndt/gfq664

Abate V, Vergatti A, Fiore A, et al. Low potassium intake: a common risk factor for nephrolithiasis in patients with high blood pressure. High Blood Press Cardiovasc Prev 2023;30:343-50. DOI: https://doi.org/10.1007/s40292-023-00587-0

Tebben PJ, Milliner DS, Horst RL, et al. Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. J Clin Endocrinol Metab 2012;97:E423-7. DOI: https://doi.org/10.1210/jc.2011-1935

Lacey DL, Grosso LE, Moser SA, et al. IL-1-induced murine osteoblast IL-6 production is mediated by the type 1 IL-1 receptor and is increased by 1,25 dihydroxyvitamin D3. J Clin Invest 1993; 91:1731-42. DOI: https://doi.org/10.1172/JCI116383

Lucato P, Trevisan C, Stubbs B, et al. Nephrolithiasis, bone mineral density, osteoporosis, and fractures: a systematic review and comparative meta-analysis. Osteoporos Int 2016; 27:3155-64. DOI: https://doi.org/10.1007/s00198-016-3658-8

Taylor EN, Feskanich D, Paik JM, Curhan GC. Nephrolithiasis and risk of incident bone fracture. J Urol 2016; 195:1482-6. DOI: https://doi.org/10.1016/j.juro.2015.12.069

Ganesan C, Thomas IC, Romero R, et al. Osteoporosis, fractures, and bone mineral density screening in veterans with kidney stone disease. J Bone Miner Res 2021;36:872-8. DOI: https://doi.org/10.1002/jbmr.4260

Dhayat NA, Schneider L, Popp AW, et al. Predictors of bone mineral density in kidney stone formers. Kidney Int Rep 2021; 7:558-67. DOI: https://doi.org/10.1016/j.ekir.2021.12.003

Sakhaee K, Maalouf NM, Poindexter J, et al. Relationship between urinary calcium and bone mineral density in patients with calcium nephrolithiasis. J Urol 2017; 197:1472-77. DOI: https://doi.org/10.1016/j.juro.2017.01.002

Fink HA, Litwack-Harrison S, Taylor BC, et al. Clinical utility of routine laboratory testing to identify possible secondary causes in older men with osteoporosis: the Osteoporotic Fractures in Men (MrOS) Study. Osteoporos Int 2017; 28:419-20. DOI: https://doi.org/10.1007/s00198-016-3805-2

Carbone LD, Hovey KM, Andrews CA, et al. urinary tract stones and osteoporosis: findings from the women's health initiative. J Bone Miner Res 2015; 30:2096-102. DOI: https://doi.org/10.1002/jbmr.2553

Rendina D, D'Elia L, Evangelista M, et al. Osteoporosis is a predictive factor for nephrolithiasis in an adult free-living caucasian population from southern italy: a longitudinal retrospective study based on a general practice database. Calcif Tissue Int 2020; 107:446-52. DOI: https://doi.org/10.1007/s00223-020-00737-9

Rendina D, De Filippo G, Iannuzzo G, et al. Idiopathic osteoporosis and nephrolithiasis: two sides of the same coin? Int J Mol Sci 2020;21:8183. DOI: https://doi.org/10.3390/ijms21218183

Gennari L, Rendina D, Falchetti A, Merlotti D. Paget's disease of bone. Calcif Tissue Int 2019;104:483-500. DOI: https://doi.org/10.1007/s00223-019-00522-3

Rendina D, De Filippo G, Merlotti D, et al. increased prevalence of nephrolithiasis and hyperoxaluria in paget disease of bone. J Clin Endocrinol Metab 2020;105:dgaa576. DOI: https://doi.org/10.1210/clinem/dgaa576

Prié D, Friedlander G. Genetic disorders of renal phosphate transport. N Engl J Med 2010;362:2399-409. DOI: https://doi.org/10.1056/NEJMra0904186

Wagner CA, Egli-Spichtig D, Rubio-Aliaga I. Updates on renal phosphate transport. Curr Opin Nephrol Hypertens 2025;34:269-75. DOI: https://doi.org/10.1097/MNH.0000000000001090

Tiosano D, Hochberg Z. Hypophosphatemia: the common denominator of all rickets. J Bone Miner Metab. 2009; 27:392-401. DOI: https://doi.org/10.1007/s00774-009-0079-1

Berndt TJ, Schiavi S, Kumar R. "Phosphatonins" and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 2005; 289:F1170-82. DOI: https://doi.org/10.1152/ajprenal.00072.2005

Alon US. Clinical practice. Fibroblast growth factor (FGF)23: a new hormone. Eur J Pediatr 2011;170:545-54. DOI: https://doi.org/10.1007/s00431-010-1382-5

Wesseling-Perry K. FGF-23 in bone biology. Pediatr Nephrol 2010;25:603-8. DOI: https://doi.org/10.1007/s00467-009-1384-6

Shimada T, Yamazaki Y, Takahashi M, et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005;289:F1088-95. DOI: https://doi.org/10.1152/ajprenal.00474.2004

Minisola S, Peacock M, Fukumoto S, et al. Tumour-induced osteomalacia. Nat Rev Dis Primers 2017; 3:17044. DOI: https://doi.org/10.1038/nrdp.2017.44

Prié D, Ravery V, Boccon-Gibod L, Friedlander G. Frequency of renal phosphate leak among patients with calcium nephrolithiasis. Kidney Int 2001; 60:272-276. DOI: https://doi.org/10.1046/j.1523-1755.2001.00796.x

Prié D, Beck L, Silve C, Friedlander G. Hypophosphatemia and calcium nephrolithiasis. Nephron Exp Nephrol 2004; 98:e50-4. DOI: https://doi.org/10.1159/000080256

Prié D, Huart V, Bakouh N, et al. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2° sodium-phosphate cotransporter. N Engl J Med 2002; 347:983-91. DOI: https://doi.org/10.1056/NEJMoa020028

Rendina D, Mossetti G, De Filippo G, et al. Fibroblast growth factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and renal phosphate leak. J Clin Endocrinol Metab 2006;91:959-63. DOI: https://doi.org/10.1210/jc.2005-1606

Rendina D, Esposito T, Mossetti G, et al. A functional allelic variant of the FGF23 gene is associated with renal phosphate leak in calcium nephrolithiasis. J Clin Endocrinol Metab 2012;97:E840-4. DOI: https://doi.org/10.1210/jc.2011-1528

Enlund-Cerullo M, Holmlund-Suila E, Valkama S, et al. Variation in the fibroblast growth factor 23 (FGF23) gene associates with serum FGF23 and bone strength in infants. Front Genet 2023; 14:1192368. DOI: https://doi.org/10.3389/fgene.2023.1192368

van't Hoff WG. Aetiological factors in paediatric urolithiasis. Nephron Clin Pract 2004;98:c45-c48. DOI: https://doi.org/10.1159/000080251

Worcester EM, Coe FL. New insights into the pathogenesis of idiopathic hypercalciuria. Semin Nephrol 2008; 28:120-32. DOI: https://doi.org/10.1016/j.semnephrol.2008.01.005

Sargent JD, Stukel TA, Kresel J, Klein RZ. Normal values for random urinary calcium to creatinine ratios in infancy. J Pediatr 1993; 123:393-7. DOI: https://doi.org/10.1016/S0022-3476(05)81738-X

Pak CY, Britton F, Peterson R, et al. Ambulatory evaluation of nephrolithiasis. Classification, clinical presentation and diagnostic criteria. Am J Med 1980;69:19-30. DOI: https://doi.org/10.1016/0002-9343(80)90521-5

Heller HJ, Zerwekh JE, Gottschalk FA, Pak CY. Reduced bone formation and relatively increased bone resorption in absorptive hypercalciuria. Kidney Int 2007;71:808-15. DOI: https://doi.org/10.1038/sj.ki.5002181

Freundlich M, Alonzo E, Bellorin-Font E, Weisinger JR. Reduced bone mass in children with idiopathic hypercalciuria and in their asymptomatic mothers. Nephrol Dial Transplant 2002;17:1396-401. DOI: https://doi.org/10.1093/ndt/17.8.1396

García-Nieto V, Navarro JF, Monge M, García-Rodríguez VE. Bone mineral density in girls and their mothers with idiopathic hypercalciuria. Nephron Clin Pract 2003; 94:c89-93. DOI: https://doi.org/10.1159/000072491

Caudarella R, Vescini F, Buffa A, et al. Bone mass loss in calcium stone disease: focus on hypercalciuria and metabolic factors. J Nephrol 2003;16:260-6.

Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med 2013 28;369:2168. DOI: https://doi.org/10.1056/NEJMx130050

Bacchetta J, Boivin G, Cochat P. Bone impairment in primary hyperoxaluria: a review. Pediatr Nephrol 2016;31:1-6. DOI: https://doi.org/10.1007/s00467-015-3048-z

Zuckerman JM, Assimos DG. Hypocitraturia: pathophysiology and medical management. Rev Urol 2009; 11:134-44.

Frassetto L, Banerjee T, Powe N, Sebastian A. Acid balance, dietary acid load, and bone effects-a controversial subject. Nutrients 2018;10:517. DOI: https://doi.org/10.3390/nu10040517

Pak CY, Peterson RD, Poindexter J. Prevention of spinal bone loss by potassium citrate in cases of calcium urolithiasis. J Urol 2002;168:31-4. DOI: https://doi.org/10.1016/S0022-5347(05)64825-2

Prot-Bertoye C, Lebbah S, Daudon M, et al. CKD and its risk factors among patients with cystinuria. Clin J Am Soc Nephrol 2015; 10:842-51. DOI: https://doi.org/10.2215/CJN.06680714

Peters T, Thaete C, Wolf S, et al. A mouse model for cystinuria type I. Hum Mol Genet 2003;12:2109-120. DOI: https://doi.org/10.1093/hmg/ddg189

Bijelic R, Milicevic S, Balaban J. Incidence of osteoporosis in patients with urolithiasis. Med Arch 2014; 68:335-8. DOI: https://doi.org/10.5455/medarh.2014.68.335-338

D’Ambrosio V, Capolongo G, Caletti C et al. Bone mineral density assessment in patients with cystinuria. J Nephrol 2025;38:163-9. DOI: https://doi.org/10.1007/s40620-024-02012-8

Sampat R, Fu R, Larovere LE, et al. Mechanisms for phenotypic variation in Lesch-Nyhan disease and its variants. Hum Genet 2011;129:71-8. DOI: https://doi.org/10.1007/s00439-010-0901-9

Chen F, Wang Y, Guo Y, et al. Specific higher levels of serum uric acid might have a protective effect on bone mineral density within a Chinesepopulation over 60 years old: a cross-sectional study from northeast China. Clin Interv Aging 2019; 14:1065-73. DOI: https://doi.org/10.2147/CIA.S186500

Dalbeth N, Becce F, Botson JK, et al. Dual-energy CT assessment of rapid monosodium urate depletion and bone erosion remodelling during pegloticase plus methotrexate co-therapy. Rheumatology (Oxford) 2022;61:4898-904. DOI: https://doi.org/10.1093/rheumatology/keac173

Hyams ES, Matlaga BR. Economic impact of urinary stones. Transl Androl Urol 2014;3:278-83.

Marcellusi A, Rotundo MA, Nardone C, et al. Osteoporosis: economic burden of disease in Italy. Clin Drug Investig 2020; 40:449-58. DOI: https://doi.org/10.1007/s40261-020-00904-8